Abstract
Oral Galactose Provides a Different Approach to Incretin-Based Therapy of Alzheimer's Disease
Highlights
Alzheimer’s disease (AD) is the most common form of dementia for which there is no cure and no approved disease-modifying therapy, and which presents as a metabolic disorder of the brain characterised by insulin-resistant brain state (IRBS)[1,2,3] and brain glucose hypometabolism[4]
Type 2 diabetes mellitus (T2DM) is a risk factor for AD5 which has increased the interest in restoring brain insulin signalling in AD with therapeutic agents originally developed for the treatment of T2DM, those stimulating the action of glucagon-like peptide-1 (GLP-1)[6,7]
This review points out another approach to the incretin-related therapy based on the recent research on oral galactose therapeutic potential in a streptozotocin-induced rat model of sAD17,18 (STZ-icv model) which develops cognitive deficits, IRBS and glucose hypometabolism in the brain[19,20]
Summary
Alzheimer’s disease (AD) is the most common form of dementia for which there is no cure and no approved disease-modifying therapy, and which presents as a metabolic disorder of the brain characterised by insulin-resistant brain state (IRBS)[1,2,3] and brain glucose hypometabolism[4]. This review points out another approach to the incretin-related therapy based on the recent research on oral galactose therapeutic potential in a streptozotocin-induced rat model of sAD17,18 (STZ-icv model) which develops cognitive deficits, IRBS and glucose hypometabolism in the brain[19,20].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
